Popular
GLUE · Medicine & biotech · U.S.

Monte Rosa Therapeutics

Develops pills that help the body clear out harmful proteins.

Company Health

35
/100
Weak
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $31 of every $100 in sales.
Is it growing?
25 of 25 · Good
Sales grew about 64% over the last year.
Can it handle what it owes?
10 of 25 · Okay
Its business used cash last year, and it owes $48 of every $100 it owns.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $22 of every $100 in sales.

Who owns it

1 of 23 own it · 1 bought more lately
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Monte Rosa Therapeutics’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales went from $0 in 2023 to $124 million in 2025, and it lost money every year.
2025
Sales
$124 million
Loss
$38.6 million

Spare cash each year

It had cash to spare in 1 of the 6 years, but in 2025 it spent $27.5 million more than it brought in.
2025
Cash shortfall
$27.5 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $449 million, including $130 million in cash, and owed $216 million.

Key facts

From its yearly report for 2025.
Sales
$124 million
Loss
$38.6 million
Cash shortfall
$27.5 million
Cash in the bank
$130 million
Everything it owes
$216 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Mar 17, 2026
Figures from Monte Rosa Therapeutics’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy